News Article
On June 17, 2020, the House Energy and Commerce Committee’s Subcommittee on Health held a hearing entitled "Health Care Inequality: Confronting Racial and Ethnic Disparities in COVID-19 and the Health Care System." The International Myeloma Foundation sent a letter of support to the committee for…
Videos
Discussing the SWOG-1211 Study Presented at ASCO 2020
Myeloma Expert Dr. Saad Usmani Discusses the SWOG-1211 Study Presented at ASCO 2020
What is the purpose of this trial?
This partially randomized phase I/II trial studies the side effects and best dose of the drug…
Videos
Dr. Parameswaran Hari on the STaMINA Study
Dr. Parameswaran Hari Discusses Long-Term Follow-Up of the STaMINA Study
What is the STaMINA study?
STaMINA was a phase III trial comparing the long-term outcomes among 758 myeloma patients undergoing single autologous transplant with or without…
Videos
IMF Chief Medical Officer Dr. Joseph Mikhael on the IKEMA Study
What is the IKEMA Trial?
The IKEMA trial is a phase III study in which patients with relapsed refractory multiple myeloma who have undergone 1-3 prior lines of therapy that were randomized 3:2. These…
Videos
Dr. Meletios A. Dimopoulos Discusses the Boston Trial
What is the BOSTON Trial?
The BOSTON trial is the first phase III study to evaluate the clinical benefit of selinexor, Velcade (bortezomib), and dexamethasone (XVd) for relapsed/refractory multiple myeloma. The BOSTON…
Videos
Dr. Saad Usmani on the DREAMM-9 Trial
What is the DREAMM-9 trial?
The DREAMM-9 trial is a phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) as the standard of care for transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma…
Videos
Belantamab mafodotin induced deep and durable responses in relapsed refractory myeloma patients
What is the DREAMM-5 platform trial?
The DREAMM-5 platform trials studies the single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugates…
Page
The death of George Floyd at the hands of the police has enraged the world. The IMF stands together with the Black community in calling for justice and racial equality. We believe unconditionally, that Black lives matter.
Because of the systemic racism that still runs rampant in our communities…
Event
Learn more about current trends in myeloma treatment and research with this update from two major medical meetings held virtually in May and June 2020.
Dr. Brian G.M. Durie will explain what’s new and exciting from:
American Society of Clinical Oncology (ASCO) Virtual Scientific…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with Jen Curran, which was recorded on February 21, 2020. Jen was the opening speaker at…
Videos
Dr. Noemi Puig on the GEM-CESAR Trial
What is the GEM-CESAR trial?
The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint is the achievement of sustained minimal residual disease (MRD…
Videos
Dr. Meletios A. Dimopoulos on the Phase III Tourmaline-MM Trial
What is the phase III TOURMALINE-MM1 trial?
Maintenance therapy delays disease progression in newly diagnosed multiple myeloma (NDMM) patients who do not undergo autologous stem cell transplant (ASCT). However…
Videos
Dr. Katja Weisel on the GMMG-CONCEPT Trial
What is the GMMG-CONCEPT trial?
The GMMG-CONCEPT trial is a clinical phase II, multicenter, open-label study which evaluates induction, consolidation, and maintenance treatment with the quadruplet regimen isatuximab plus carfilzomib,…
Videos
Dr. Sundar Jagannath on the KarMMa Study
What is the KarMMa study?
KarMMa is a pivotal, open-label, single-arm, multicenter, multinational, phase II study evaluating the efficacy and safety of ide-cel in adult patients with relapsed and refractory multiple myeloma (RRMM) in…
Videos
Dr. Hans Lee on the DREAMM-2 Trial
What is the DREAMM-2 Trial?
DREAMM-2 is an open-label study of belantamab mafodotin. Patients in the trial had actively progressing multiple myeloma that had worsened despite current standard of care and were randomized to two arms to receive…
Videos
Continuing his COVID-19 FAQ series, Dr. Brian G.M. Durie discusses if myeloma patients should undergo autologous stem cell transplant (ASCT) and stem cell harvesting during the global health crisis.
BOTTOM LINE:
It is recommended to delay ASCT and stem cell harvesting. If…
Videos
Dr. Ajay Nooka on the DREAMM-6 Trial
What is the DREAMM-6 trial?
The DREAMM-6 trial studies belantamab mafodotin (Bela), a B-cell maturation antigen targeting immunoconjugate. Bela has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-…
Videos
Dr. Shaji Kumar on the ENDURANCE Trial
What is the ENDURANCE trial?
The ENDURANCE (E1A11) phase III trial compares the combination of the drugs bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone when treating patients…
Videos
Dr. Xavier Leleu on the CANDOR and MMY1001 Studies
What are the CANDOR and MMY1001 studies?
The CANDOR trial is a randomized phase III study that compares the efficacy of Kyprolis (carfilzomib), dexamethasone, and Darzalex (daratumumab) (KdD) to Kyprolis…
Videos
Dr. Meera Mohan on MRD Evolution in Patients Who Have Reached an Optimal Endpoint
What was the goal of this study?
The attainment of minimal residual disease (MRD) negativity in multiple myeloma (MM) patients is increasingly considered an optimal therapeutic endpoint, but…
Videos
Dr. Benjamin A. Derman on Mass Spectrometry
What is the purpose of this study?
This study assesses the concordance of mass spectometry in peripheral blood and Next-Generation Sequencing (NGS) in the bone marrow, comparing outcomes by minimal residual disease status.…
Videos
Continuing his COVID-19 FAQ series, Dr. Brian G.M. Durie discusses when myeloma patients should return to the clinic and if virtual doctors' visits are still considered to be safer.
BOTTOM LINE:
Carefully discuss with your doctor if it is possible to continue virtual visits.…
Audio
In this episode of “Conversations with Dr. Brian Durie,” Dr. Durie is joined by Dr. Suzanne Lentzsch of the New York-Presbyterian Hospital, and IMF Board Member and myeloma patient Yelak Biru. Listen as Dr. Suzanne Lentzsch describes her experience working on the front lines of the COVID-19…
Videos
Continuing his COVID-19 FAQ series, Dr. Brian G.M. Durie discusses if myeloma patients taking Revlimid as a maintenance therapy should consider altering their treatment.
BOTTOM LINE:
Stick to your Revlimid maintenance therapy despite the COVID-19 crisis and discuss any…
Videos
MGUS, Smoldering Multiple Myeloma, and COVID-19
Continuing his COVID-19 FAQ series, Dr. Brian G.M. Durie addresses whether MGUS and smoldering multiple myeloma patients are at a higher risk of infection and severe consequences from the COVID-19 virus.
BOTTOM LINE:…
Videos
The tenth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses the COVID-19 antibody test, and if it is useful for myeloma patients
BOTTOM LINE:
Routine COVID-19 antibody testing is not currently recommended for myeloma…
News Article
The entire International Myeloma Foundation team is saddened by the passing of our very dear friend Fred Willard.
Through the years, Fred performed at the IMF's Annual Comedy Celebration. We are forever grateful for the countless volunteer performances he gave to his fans at our largest…
Videos
The ninth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie outlines how myeloma patients can stay dafe during the COIVD-19 pandemic.
BOTTOM LINE:
Until there is a vaccine, it is possible to avoid contacting the COVID-19…
Audio
Hosted by Dr. Brian G.M. Durie, world-renowned myeloma expert and Chairman of the Board of the International Myeloma Foundation, the "Conversations with Dr. Durie" podcast focuses on inspirational and educational topics that are relevant to the myeloma community and beyond.
In this episode, Dr.…
Videos
The eighth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses if physical distancing is still necessary for myeloma patients as states begin reopening.
BOTTOM LINE:
During the reopening process, myeloma…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation (IMF) features messages of hope and resilience for myeloma patients, caregivers, and their loved ones.
In Memoriam: We recorded the following interview with Mark Ho on April 17, 2020. Unfortunately,…
Videos
The seventh episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses how myeloma patients can safely take walks during the shelter-at-home order.
BOTTOM LINE:
It is healthy to get fresh air and exercise. …
Videos
The sixth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses which the precautions myeloma patients should take when procuring groceries and other essentials.
BOTTOM LINE:
It is recommended to have all essentials delivered to…
Videos
The fifth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses which factors increase a myeloma patient's risk for developing serious consequences from the COVID-19 Infection.
BOTTOM LINE:
While myeloma patients do need to be…
Videos
The fourth episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses various treatment adjustments myeloma patients can consider to reduce the risk of infection.
BOTTOM LINE:
There are several treatment adjustments that can be made to…
Videos
Double-click on the image above to view a replay of the teleconference.
DOWNLOAD SLIDES
As the COVID-19 respiratory virus spreads across the country and…
Videos
In the third episode of his ten-episode COVID-19 FAQ series, Dr. Brian G.M. Durie discusses if myeloma patients should consider adjusting their treatment.
BOTTOM LINE:
To minimize the risk of infection, myeloma patients may need to adjust their treatment or…
Videos
The second episode of his ten episode COVID-19 FAQ series, Dr. Brian G.M. Durie addresses what exactly myeloma patients need to know about the novel coronavirus.
BOTTOM LINE:
COVID-19 is highly infectious. Myeloma patients should take extra precautions to avoid…
Videos
In this week’s video, Dr. Durie addresses a frequently asked question from myeloma patients on how to reduce COVID-19 exposure.
BOTTOM LINE:
To reduce the risk of being exposed:
• Stay in your home.
• Maintain a physical distance of six feet from others…
Page
Brief Overview: The Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 was the first piece of legislation passed to address COVID-19. This bill was an emergency supplemental appropriations bill (spending bill) that can be viewed…
Page
Food and Nutrition Services Safety Net Programs
FY2020 supplemental appropriations to the Department of Agriculture (USDA) for nutrition and food assistance programs, including:
The Special Supplemental Nutrition Program for Women, infants, and Children (WIC…
Page
Brief Summary: The Corona Virus Aid, Relief, and Economic Security Act (CARES) Act was signed into law on March 27, 2020. The bill provides financial relief for the American public and American businesses while also providing additional public health funding to combat the virus.…
Page
Defense Production Act
On March 20th, President Trump stated he had invoked his emergency war powers under the Defense Production Act to direct private businesses to produce and distribute medical supplies in anticipation of a surge in demand. As of April 16th, it is our understanding that the…
Videos
In this week’s video, Dr. Durie discusses what options myeloma patients have when drug side effects impact their quality of life.
BOTTOM LINE:
Discuss treatment changes carefully with your doctor.
Transcript:
This week's “Ask Dr. Durie” comes from a…
News Article
To the Myeloma Community,
We wanted to take some time and to keep you up to date on the Federal Government’s response regarding COVID-19. We have received a lot of questions from patients and their families about what is included in the response, and what the government has done…
News Article
The International Myeloma Foundation is very pleased to announce that Martine Elias has joined the IMF Board of Directors. Martine brings tremendous experience and commitment to the Board, and the IMF looks forward to her active involvement in our many programs.
Martine Elias is the…
Page
Get the Latest Information on COVID-19 for Myeloma Patients
Know your COVID-19 Community Level, read up on the IMF's latest recommendations and answers to FAQs on COVID-19 vaccines, boosters, anti-viral treatments, and more.
Videos
In this week’s video, Dr. Durie discusses the FDA approval of the drug Sarclisa (isatuximab), and how the drug can benefit multiple myeloma patients.
BOTTOM LINE:
Sarclisa is a new drug approved for use in combination therapy for myeloma patients in the relapse setting…